Replies to post #163148 on Biotech Values

[jq1234]

HSP-Celltrion biosimilar partnership is different from most.

Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today signed a Business Cooperation Agreement with South Korea-based Celltrion, Inc. and Celltrion Healthcare, Inc. ("Celltrion"), which outlines the business terms of a future distribution agreement for the United States, Europe, Australia, New Zealand and Canada for eight biogeneric products that are currently under development by Celltrion, five of which are incremental to Hospira's pipeline. Under the distribution agreement, the parties would collaborate on manufacturing and supply of the products. After regulatory approval, Hospira and Celltrion would co-exclusively market the drugs, with the products independently commercialized under each party's brand name.

http://www.prnewswire.com/news-releases/hospira-celltrion-enter-business-cooperation-agreement-to-develop-and-market-biogeneric-drugs-63765702.html